1. Can COVID-19 Be a Potential Risk Factor for Voriconazole-Induced Hyperkalemia?
- Author
-
Mounir Benjemaa, Hana Chaabouni, I. Bougharriou, Khaled Zghal, Salma Ben Hmida, and Hanen Ghozzi
- Subjects
Antifungal ,Drug ,Voriconazole ,medicine.medical_specialty ,Hyperkalemia ,Candida glabrata ,biology ,Coronavirus disease 2019 (COVID-19) ,Potential risk ,medicine.drug_class ,business.industry ,media_common.quotation_subject ,nutritional and metabolic diseases ,Ocean Engineering ,Inflammation ,urologic and male genital diseases ,biology.organism_classification ,Gastroenterology ,Internal medicine ,medicine ,medicine.symptom ,Safety, Risk, Reliability and Quality ,business ,media_common ,medicine.drug - Abstract
Voriconazole is an antifungal agent that is commonly used to treat fungal infections. Like any drug, it can cause side effects, especially in the case of overdose. Few cases of hyperkalemia have been reported, which presented when the serum voriconazole level was elevated or when there was voriconazole-drug interaction. We present here a case of voriconazole-induced hyperkalemia, prescribed for an oral candidiasis due to Candida glabrata in a patient hospitalized for severe COVID-19 pulmonary infection. Inflammation due to COVID-19 may play a role in the variability of voriconazole concentrations and then in hyperkalemia.
- Published
- 2021
- Full Text
- View/download PDF